A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)-Reference-Cited by-同舟云学术

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)

Published:2024-01 Issue: Volume:196 Page:113455
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Dayimu Alimu^ORCID,Gupta Avinash,Matin Rubeta N.,Nobes Jenny^ORCID,Board Ruth,Payne Miranda,Rao Ankit,Fusi Alberto,Danson Sarah,Eccles Bryony,Carser Judith,Brown Ciara O’Hanlon,Steven Neil,Bhattacharyya Madhumita,Brown Ewan,Gonzalez Michael,Highley Martin,Pickering Lisa,Kumar Satish,Waterston Ashita^ORCID,Burghel George^ORCID,Demain Leigh,Baker Eleanor,Wulff Jerome^ORCID,Qian Wendi,Twelves Sophie^ORCID,Middleton Mark^ORCID,Corrie Pippa^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma;Robert;N Engl J Med,2019

2. 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study;Ascierto;Clin Cancer Res,2021

3. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma [published correction appears in J Clin Oncol. 2023 Apr 20;41(12):2301];Dummer;J Clin Oncol,2022

4. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E);Poulikakos;Nature,2011

5. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance;Alcalá;Clin Cancer Res,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting;Melanoma Research;2024-08-30